SS-31 (Elamipretide)

Quick Facts

Introduction

SS-31, known in clinical-stage investigation as elamipretide, is one of the most studied members of the mitochondria-targeted peptide family. Unlike the receptor-binding compounds that dominate much of peptide research, SS-31's defining behavior is physicochemical: it concentrates inside mitochondria and associates with a single, specialized membrane lipid. That focus on the inner mitochondrial membrane makes it a distinctive tool for researchers interested in cellular energy production.

The appeal of a mitochondria-targeted compound is straightforward to state. Mitochondria are the cell's primary site of ATP production, and the inner mitochondrial membrane is where the electron transport chain assembles. When that membrane and its specialized lipid environment become disorganized — as happens in aging, ischemia, and a range of stress states — energy output falls and reactive oxygen species rise. A molecule that concentrates precisely at that membrane therefore offers researchers a way to probe whether stabilizing the structure itself can preserve function. SS-31 is the most thoroughly studied compound built around that premise.

This profile examines what SS-31 is, the structural features that drive its mitochondrial targeting, its cardiolipin-centered mechanism, the bioenergetic research it is most associated with, and how it compares with other mitochondrial compounds such as MOTS-c and humanin. Related compounds are catalogued in the peptide database, and additional profiles are being added to the Research Library.

What is SS-31?

SS-31 is a synthetic aromatic-cationic tetrapeptide belonging to the Szeto-Schiller (SS) family of mitochondria-targeting peptides. Its sequence — D-Arg-Dmt-Lys-Phe-NH2 — alternates basic (cationic) and aromatic residues, a structural signature that allows the molecule to cross the outer mitochondrial membrane and accumulate within the inner membrane.

The use of a D-arginine residue and the amidated C-terminus contribute to stability against peptidases, while the 2,6-dimethyltyrosine (Dmt) provides an aromatic anchor. Together these features make SS-31 unusually small and stable for a targeting peptide, which is part of why it has been advanced into clinical-stage research under the name elamipretide.

Molecular and structural characteristics

The alternating aromatic/cationic architecture is the central structural fact about SS-31. Most cationic molecules that enter mitochondria do so because they are drawn by the steep electrochemical gradient across the inner membrane (the membrane potential). SS-31 is notable because its accumulation is reported to be largely independent of membrane potential — an important property, since depolarized or stressed mitochondria, which are often the research target, may have a diminished gradient.

Mechanism of action

SS-31 does not act on a cell-surface receptor. After entering the cell, it accumulates several thousand-fold in the inner mitochondrial membrane, where it binds cardiolipin — a phospholipid found almost exclusively in that membrane. Cardiolipin is not a passive structural lipid: it scaffolds the respiratory supercomplexes of the electron transport chain and helps maintain the tightly folded cristae architecture where oxidative phosphorylation occurs.

By associating with cardiolipin, SS-31 is studied for its capacity to preserve cristae organization, support efficient electron transport, and reduce the leakage of electrons that generates reactive oxygen species. In stressed or aged mitochondrial models, where cardiolipin is often peroxidized or disorganized, this interaction is the proposed basis for the bioenergetic effects researchers report.

A subtle but important point distinguishes SS-31 from conventional antioxidants. Rather than simply scavenging free radicals after they form, the mechanism researchers propose is structural: by helping cardiolipin keep the respiratory supercomplexes correctly assembled, SS-31 is studied for reducing the inefficient electron transfer that produces excess reactive oxygen species in the first place. In this framing, lower oxidative stress is a downstream consequence of better-organized bioenergetics rather than the primary action — a distinction that shapes how investigators design and interpret their experiments.

1. SS-31 crosses cell and outer mitochondrial membranes via its aromatic-cationic structure.
2. It accumulates in the inner mitochondrial membrane, largely independent of membrane potential.
3. It binds cardiolipin, the scaffold lipid of respiratory supercomplexes.
4. Association is studied for preserving cristae architecture and electron-transport efficiency.
5. Downstream, researchers track reduced reactive oxygen species generation.

Mitochondrial bioenergetics research

The core research domain for SS-31 is mitochondrial bioenergetics. In isolated mitochondria and cell models, investigators examine endpoints such as ATP production efficiency, oxygen consumption rate, and the integrity of the electron transport chain. Because SS-31 targets the structural lipid that organizes that chain, it is used to ask whether stabilizing cardiolipin translates into measurable improvements in energy output under stress.

A common experimental approach is to subject isolated mitochondria or cultured cells to a defined stressor — hypoxia, a toxin, or simulated ischemia — and then compare bioenergetic readouts with and without SS-31 present. Endpoints such as the respiratory control ratio, maximal respiration, and the rate of ATP synthesis allow researchers to quantify whether the compound preserves function under conditions that would otherwise degrade it. The recurring narrative in this literature is one of resilience: SS-31 is studied less for boosting healthy mitochondria and more for protecting stressed ones.

Cardiac, muscle, and oxidative-stress research

Because tissues differ enormously in how much they depend on mitochondrial energy, researchers concentrate SS-31 studies in organs where bioenergetic capacity is the rate-limiting factor. Cardiac muscle is the archetype: the heart is among the most mitochondria-dense tissues in the body, and its continuous workload makes it acutely sensitive to any decline in energy supply. Ischemia-reperfusion models — in which blood flow is interrupted and then restored — are a frequent context, because the reperfusion phase generates a burst of reactive oxygen species that damages mitochondria precisely where cardiolipin organization matters most.

Skeletal muscle is a second major focus, particularly in models of aging where mitochondrial function and exercise capacity decline together. Here investigators examine whether stabilizing the inner membrane translates into measurable preservation of muscle bioenergetics. Across both tissue types, the unifying readout is oxidative stress: markers such as lipid peroxidation, reactive oxygen species, and indicators of mitochondrial membrane integrity are tracked to connect the structural mechanism to a functional outcome.

These tissue-level studies are also where the gap between mechanism and applied result becomes visible. Encouraging preclinical bioenergetic data have not always carried over into clinical-stage work under the name elamipretide, a theme addressed in the research-limitations section below.

Comparison: SS-31 vs MOTS-c vs Humanin

SS-31 is frequently contrasted with the mitochondrial-derived peptides MOTS-c and humanin. The distinction is mechanistic: the mitochondrial-derived peptides act largely through signaling pathways, whereas SS-31's primary studied action is a direct lipid interaction. It is also compared with broadly distributed antioxidant small molecules such as coenzyme Q10, against which its inner-membrane selectivity stands out.

Dedicated profiles for MOTS-c and other mitochondrial compounds are catalogued in the peptide database and are being expanded in the Research Library.

Half-life and pharmacokinetic considerations

Pharmacokinetic reports describe SS-31 as having a relatively short plasma half-life after subcutaneous administration. As with many targeted compounds, however, plasma concentration is an incomplete descriptor: SS-31 partitions strongly into mitochondria-rich tissues, so tissue exposure can substantially exceed what circulating levels alone would predict.

For researchers, this means tissue accumulation is often a more meaningful readout than plasma half-life when interpreting effect. The compound's strong partitioning into the inner mitochondrial membrane is the pharmacokinetic counterpart to its mechanism — it is designed to leave the bloodstream and concentrate where it acts.

This pharmacokinetic-pharmacodynamic disconnect has practical consequences for study design. A sampling schedule that tracks only plasma levels can substantially underestimate exposure at the site of action, so researchers commonly pair plasma measurements with tissue-level or functional readouts. It is a useful reminder that for a targeted compound, where the molecule goes matters more than how long it lingers in blood — and interpreting SS-31 data without accounting for its mitochondrial partitioning can be misleading.

Reconstitution and handling considerations

SS-31 reconstitutes readily in sterile or bacteriostatic water owing to its good aqueous solubility. As with other peptides, diluent is added gently against the vial wall and the vial is swirled rather than shaken to avoid foaming and shear stress. The resulting solution should be clear and colorless; any cloudiness indicates the preparation should be discarded.

Working concentration is chosen so research volumes are convenient to measure. The reconstitution calculator and reconstitution guide cover the general approach.

• Add diluent slowly; swirl gently to dissolve.
• Confirm the solution is clear and colorless before use.
• Select a working concentration that makes research volumes reproducible.
• Protect from light and excess warmth during handling.

Storage considerations

Lyophilized SS-31 is most stable stored frozen at −20 °C, protected from light and moisture. Once reconstituted, it is refrigerated at 2–8 °C, used within a limited window, and protected from repeated freeze–thaw cycles to preserve integrity. Aliquoting is a common strategy to limit how often a solution is cycled.

Research limitations

SS-31 is an investigational research compound, and its findings are tied to the specific experimental systems in which they were generated. Mitochondrial effects are model- and concentration-dependent, and results from isolated mitochondria or cell culture may differ from those in intact-organism studies. Notably, clinical-stage research under the name elamipretide has produced mixed outcomes across indications, which underscores the gap between mechanistic promise and applied results.

• Findings are bound to their experimental systems; extrapolation is unwarranted.
• Effects are model- and concentration-dependent.
• Isolated-system results may not transfer to intact organisms.
• Clinical-stage (elamipretide) outcomes have been mixed across indications.

Frequently Asked Questions

Related Research Profiles

References

1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014.Source
2. Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013.Source